RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...
L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...
Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.75 | 4.91071428571 | 56 | 59.2 | 55.9 | 296686 | 57.81279925 | DE |
4 | 7.35 | 14.2996108949 | 51.4 | 59.2 | 51.15 | 299179 | 55.14316697 | DE |
12 | 7.25 | 14.0776699029 | 51.5 | 59.2 | 49.16 | 279958 | 52.65872913 | DE |
26 | 9.31 | 18.8309061489 | 49.44 | 59.2 | 47.98 | 254530 | 52.10986989 | DE |
52 | 8.25 | 16.3366336634 | 50.5 | 59.2 | 47.28 | 243482 | 51.24589667 | DE |
156 | 8.95 | 17.9718875502 | 49.8 | 59.2 | 34.52 | 236468 | 45.7184774 | DE |
260 | 20.11 | 52.0445134576 | 38.64 | 59.2 | 28.26 | 279163 | 45.32450483 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約